Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aripiprazole + quetiapine + risperidone
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a group of three second-generation (atypical) antipsychotic medications—aripiprazole, quetiapine, and risperidone—that are frequently grouped together as 'usual care' in clinical trials, such as the Northwell Health-sponsored study (NCT01844700) evaluating weight gain in pediatric patients. These small-molecule drugs are characterized by their modulation of dopamine and serotonin receptors. Aripiprazole (Abilify) is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A. Quetiapine (Seroquel) acts as an antagonist at dopamine D1/D2, serotonin 5-HT2A, histamine H1, and alpha-1 adrenergic receptors. Risperidone (Risperdal) is a potent antagonist at dopamine D2 and serotonin 5-HT2A receptors. All three agents are FDA-approved for the treatment of schizophrenia, bipolar I disorder, and irritability associated with autism spectrum disorder, and they are being investigated for use in severe mood dysregulation.
- Brand names
- AbilifySeroquelRisperdal
02
Targets
HTR2A (5-hydroxytryptamine receptor 2A)DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)ADRA1 (Alpha-1 adrenergic receptor family)HRH1 (Histamine H1 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on aripiprazole + quetiapine + risperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aripiprazole + quetiapine + risperidone.